Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) London – 9 October 2024 - Purespring Therapeutics, a…
Read More
KIDNEY DISEASES
Treat kidneys, transform lives.
At Purespring, we are leading a revolution in the treatment of kidney diseases. The main function of the kidneys is to filter water and waste products out of the blood to create urine. The main filtering units are the glomeruli, which are largely made up of podocytes.
The Purespring technology enables delivery of gene therapies specifically to podocytes, creating an opportunity to create novel treatments for a range of genetic and non-genetic glomerular kidney diseases.
0
million
Suffer from kidney disease globally
0
%
Suffer from rare kidney diseases
0
%
Patients on dialysis developed kidney failure due to a rare kidney disease
Currently over 840 million people globally suffer from chronic kidney disease. Among those 5-10% suffer from rare kidney diseases, the majority of which arise from the glomeruli and involves podocytes. Rare kidney diseases are generally associated with a worse outcome, and approximately 25% of patients on dialysis developed kidney failure due to a rare kidney disease. Purespring exists to change the course of glomerular kidney diseases by providing transformative treatments to make a real difference to patient lives.
Therapeutic innovation has been lacking in renal treatments, and patients are in dire need of new options. At Purespring, we are working toward a future where patients with glomerular kidney disease are empowered with therapies to change the course of their disease.
At present, when patients progress to end-stage renal disease, they are faced with two options, dialysis or kidney transplant, both of which are burdensome, and adversely affect their quality of life with continued risk of complications. Our mission is to bring disease-modifying therapies to these patients. By creating therapies to keep patients with glomerular diseases out of dialysis Purespring will create value for patients, healthcare providers and the broader society.
By bringing the power of gene therapy specifically to podocytes, we aim to stop glomerular kidney diseases in their tracks, and to do so as soon as possible. At Purespring, we are looking to change the status quo, and to do it now with gene therapies designed to target both inherited and common kidney diseases.
OUR PIPELINE
Imagine a near future where patients with kidney diseases are empowered with therapies to change the course of their disease.
The lead program is PS-002, which controls complement signalling exclusively in the glomeruli, and therefore has the potential to treat a range of glomerular diseases driven by complement activation. PS-002 development will initially focus on IgA nephropathy, and eventually broaden to other complement driven glomerular diseases.
Subsequent Purespring programs will focus on nephropathies driven by monogenic podocyte disorders including NPHS2 nephropathy, glomerular basal membrane deficiencies and a range of other genetic and non-genetic glomerular diseases.
SCIENCE
The first gene therapy platform to specifically target kidney diseases.
We understand kidney diseases like nobody else. Based on decades of research from our scientific founder, Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, we now understand that the key to unlocking kidney health is the podocyte, a cell type vital to kidney function. This is why we are developing a proprietary platform and novel treatments focused on targeting the podocyte.
MORE
